The Wall Street Journal (online registration required): The U.S. Food and Drug Administration has become aware of cognitive adverse events related to a closely watched group of experimental cholesterol drugs being developed by large drug firms, Sanofi SA said in a regulatory filing Friday.
The FDA has asked Sanofi and Regeneron Pharmaceuticals Inc., which are co-developing one of the drugs, known as PCSK9 inhibitors, to assess the potential for their drug to cause neurocognitive adverse...
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now